FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096976675> ?p ?o ?g. }

• W3096976675 endingPage "6" @default.
• W3096976675 startingPage "5" @default.
• W3096976675 abstract "Background: Triplet combination regimens have been widely accepted as the standard of care for the management of multiple myeloma (MM) due to improved outcomes as compared to doublet regimens. The combination of daratumumab, pomalidomide, and dexamethasone (DPd) has previously demonstrated deep and durable responses including high rates of minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) MM. Quadruplet regimens may further improve these outcomes. We report preliminary findings from an ongoing phase 2 multi-center trial of the addition of ixazomib to DPd (DIPd) in patients with R/R MM. Methods: We are conducting a prospective, multi-center, open-label, single-arm phase 2 study to determine the efficacy and safety of DIPd as salvage therapy in R/R MM. A Simon's optimal 2-stage design includes a safety run-in period at the beginning of Stage 1 where the first 6 patients are enrolled for toxicity assessment. If ≤1 patient experiences any DLT, the study continues to accrue more Stage 1 patients. Key secondary endpoints include progression-free survival (PFS), overall survival (OS) and MRD-negativity rates. Eligible patients may have received ≥1 and ≤3 prior lines of therapy, have had no prior exposure to daratumumab or ixazomib, are lenalidomide refractory, and may have not progressed on prior pomalidomide. The first six patients were treated in a safety run-in with daratumumab 16mg/kg IV weekly x 8 doses, biweekly x 8 doses, then monthly, pomalidomide 4mg orally daily on days 1-21 of a 28-day cycle, ixazomib 4mg orally daily on days 1,8,15 every 28 days, and dexamethasone 20-40mg weekly. Patients continued therapy until disease progression, intolerability or preference. Dose-limiting toxicities (DLT) were defined as grade 3-4 hematologic adverse events (AE) or any AE that required a dose modification of pomalidomide or ixazomib at the lowest dose levels on a dose de-escalation plan. An interim safety review is being performed after the enrollment and completion of the DLT observation period for the 14 planned patients in stage I. An interim efficacy analysis was also planned after all patients had completed 3 months of therapy. Minimal residual disease assessments are being performed by EuroFlow for patients in VGPR or suspected CR. Pharmacodynamic changes in patients' tumor microenvironments were established by custom panel mass cytometry to include T-cell memory and activated subpopulations, B-cell content, NK-cell subpopulations as well as MDSCs, Tregs and T-exhaustive markers, monocytes and dendritic cells. Results: At the time of this analysis, all 14 patients have enrolled and started treatment as part of stage I of the trial. Patients had a median age of 61 (range 52-65) and median number of 1 prior line of therapy (range 1-3). All patients were refractory to lenalidomide and all were pomalidomide naïve. In the safety run-in, all 6 patients experienced ≥ grade 3 neutropenia, and per DSMB recommendation, the starting doses of pomalidomide and ixazomib were both reduced to 3mg for the subsequent 8 patients in stage 1. Common AEs included neutropenia, thrombocytopenia, and upper respiratory infection. Grade 3-4 AEs were predominantly hematologic, including neutropenia and thrombocytopenia. One patient had a grade 3 infusion-related reaction (IRR) with daratumumab administration. No DLTs have occurred. After median follow up of 4.1 months (range 1-22), all 14 patients were evaluable for efficacy. At the time of data analysis, the overall response rate to date is 85%, and the best responses include: 5 (36%) stringent complete response; 1 (7%) very good partial response; 5 (36%) partial responses; and 3 (21%) patients with stable disease. Six (42%) patients are off study treatment: 3 due to disease progression, 1 to undergo salvage autologous SCT, and 2 due to toxicity related to treatment (IRR and upper respiratory infection). MRD and pharmacodynamic data will be presented at ASH. Conclusion: The quadruplet regimen DIPd in patients with R/R MM is a well-tolerated combination and has shown early safety and promising efficacy in the first 14 patients enrolled to stage 1 of the trial. A pre-planned interim efficacy analysis is ongoing prior to future enrollment in stage 2 at multiple sites within the University of California Hematologic Malignancies Consortium. Disclosures Costello: Celgene: Honoraria, Research Funding; Janssen: Research Funding; Poseida Therapeutics: Research Funding; Takeda: Consultancy, Honoraria, Research Funding. Wieduwilt:Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees; Shire: Research Funding; Macrogeneics: Research Funding; Amgen: Research Funding; Leadiant: Research Funding; Merck: Research Funding; Reata Pharmaceuticals: Current equity holder in publicly-traded company. Shah:GSK, Amgen, Indapta Therapeutics, Sanofi, BMS, CareDx, Kite, Karyopharm: Consultancy; BMS, Janssen, Bluebird Bio, Sutro Biopharma, Teneobio, Poseida, Nektar: Research Funding." @default.
• W3096976675 created "2020-11-09" @default.
• W3096976675 creator A5007647176 @default.
• W3096976675 creator A5053904944 @default.
• W3096976675 creator A5065883808 @default.
• W3096976675 creator A5070794158 @default.
• W3096976675 creator A5080911058 @default.
• W3096976675 creator A5089064532 @default.
• W3096976675 date "2020-11-05" @default.
• W3096976675 modified "2023-09-29" @default.
• W3096976675 title "Phase 2 Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone As Salvage Therapy in Relapsed/Refractory Multiple Myeloma: Stage I Results" @default.
• W3096976675 doi "https://doi.org/10.1182/blood-2020-143147" @default.
• W3096976675 hasPublicationYear "2020" @default.
• W3096976675 type Work @default.
• W3096976675 sameAs 3096976675 @default.
• W3096976675 citedByCount "0" @default.
• W3096976675 crossrefType "journal-article" @default.
• W3096976675 hasAuthorship W3096976675A5007647176 @default.
• W3096976675 hasAuthorship W3096976675A5053904944 @default.
• W3096976675 hasAuthorship W3096976675A5065883808 @default.
• W3096976675 hasAuthorship W3096976675A5070794158 @default.
• W3096976675 hasAuthorship W3096976675A5080911058 @default.
• W3096976675 hasAuthorship W3096976675A5089064532 @default.
• W3096976675 hasBestOaLocation W30969766751 @default.
• W3096976675 hasConcept C121332964 @default.
• W3096976675 hasConcept C126322002 @default.
• W3096976675 hasConcept C141071460 @default.
• W3096976675 hasConcept C142424586 @default.
• W3096976675 hasConcept C143998085 @default.
• W3096976675 hasConcept C2776063141 @default.
• W3096976675 hasConcept C2776364478 @default.
• W3096976675 hasConcept C2776694085 @default.
• W3096976675 hasConcept C2778524551 @default.
• W3096976675 hasConcept C2780108899 @default.
• W3096976675 hasConcept C2780775027 @default.
• W3096976675 hasConcept C2781098529 @default.
• W3096976675 hasConcept C2781119759 @default.
• W3096976675 hasConcept C71924100 @default.
• W3096976675 hasConcept C87355193 @default.
• W3096976675 hasConceptScore W3096976675C121332964 @default.
• W3096976675 hasConceptScore W3096976675C126322002 @default.
• W3096976675 hasConceptScore W3096976675C141071460 @default.
• W3096976675 hasConceptScore W3096976675C142424586 @default.
• W3096976675 hasConceptScore W3096976675C143998085 @default.
• W3096976675 hasConceptScore W3096976675C2776063141 @default.
• W3096976675 hasConceptScore W3096976675C2776364478 @default.
• W3096976675 hasConceptScore W3096976675C2776694085 @default.
• W3096976675 hasConceptScore W3096976675C2778524551 @default.
• W3096976675 hasConceptScore W3096976675C2780108899 @default.
• W3096976675 hasConceptScore W3096976675C2780775027 @default.
• W3096976675 hasConceptScore W3096976675C2781098529 @default.
• W3096976675 hasConceptScore W3096976675C2781119759 @default.
• W3096976675 hasConceptScore W3096976675C71924100 @default.
• W3096976675 hasConceptScore W3096976675C87355193 @default.
• W3096976675 hasIssue "Supplement 1" @default.
• W3096976675 hasLocation W30969766751 @default.
• W3096976675 hasOpenAccess W3096976675 @default.
• W3096976675 hasPrimaryLocation W30969766751 @default.
• W3096976675 hasRelatedWork W2478188943 @default.
• W3096976675 hasRelatedWork W2615497162 @default.
• W3096976675 hasRelatedWork W2731606591 @default.
• W3096976675 hasRelatedWork W2734396891 @default.
• W3096976675 hasRelatedWork W2980429921 @default.
• W3096976675 hasRelatedWork W2980849131 @default.
• W3096976675 hasRelatedWork W2981066129 @default.
• W3096976675 hasRelatedWork W3095535753 @default.
• W3096976675 hasRelatedWork W3114717300 @default.
• W3096976675 hasRelatedWork W3170905114 @default.
• W3096976675 hasVolume "136" @default.
• W3096976675 isParatext "false" @default.
• W3096976675 isRetracted "false" @default.
• W3096976675 magId "3096976675" @default.
• W3096976675 workType "article" @default.